5 November 2026 in Cancer Discovery
Acute myeloid leukemia (AML) is characterized by significant immunosuppression, limiting the efficacy of immunotherapy. Monocytic AML presents unique immunosuppressive features and constitutes a challenging subtype, necessitating focused investigation. Using single-cell multiomic analyses of primary AML samples, we revealed the immunosuppression landscape of monocytic AML and identified biliverdin reductase B (BLVRB) as a marker of immunosuppressive monocytic AML cells. BLVRB depletion downregulated immunomodulatory gene expression and sensitized AML cells to T-cell cytotoxicity, resulting in improved therapeutic efficacy in cell line–derived xenograft (CDX) and patient-derived xenograft (PDX) models. Mechanistically, BLVRB signals through the transcription factor MAFB to promote the expression of various immunosuppression-associated genes, resulting in inhibitory effects against anti-AML T cells. We further demonstrated that the small-molecule tamibarotene targets BLVRB, enhancing the efficacy of both chimeric antigen receptor (CAR) T and anti–PD-1 antibody therapies in AML. These findings elucidate the critical mechanism regulating immunosuppression in monocytic AML and identify BLVRB as a therapeutic target for improving AML immunotherapy. Significance: We revealed the particularly immunosuppressive feature of the monocytic AML subset and identified BLVRB-targeting strategies to reverse AML immunosuppression. Genetic disruption or pharmacologic inhibition of BLVRB sensitized AML cells to T cell–mediated cytotoxicity, offering potential strategies to enhance the therapeutic potency of immunotherapy against AML.